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Abstract
Background: Modified median and subgroup-specific gene centering are two essential pre-
processing methods to assign breast cancer molecular subtypes by PAM50. We evaluated the 
PAM50 subtypes derived from both methods in a subset of Nurses’ Health Study (NHS) and 
NHSII participants; correlated tumor subtypes by PAM50 with immunohistochemistry (IHC) 
surrogates; and characterized the PAM50 subtype distribution, proliferation scores and risk of 
relapse with proliferation and tumor size weighted (ROR-PT) scores in the NHS/NHSII.
Methods: PAM50 subtypes, proliferation scores and ROR-PT scores were calculated for 882 
invasive breast tumors and 695 histologically normal tumor-adjacent tissues. Cox proportional 
hazard models evaluated the relationship between PAM50 subtypes or ROR-PT scores/groups with 
recurrence free survival (RFS) or distant RFS.
Results: PAM50 subtypes were highly comparable between the two methods. The agreement 
between tumor subtypes by PAM50 and IHC surrogates improved to fair when Luminal subtypes 
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were grouped together. Using the modified median method, our study consisted of 46% Luminal 
A, 18% Luminal B, 14% HER2-enriched, 15% Basal-like and 8% Normal-like subtypes; 53% of 
tumor-adjacent tissues were Normal-like. Women with the Basal-like subtype had a higher rate of 
relapse within five years. HER2-enriched subtypes had poorer outcomes prior to 1999.
Conclusion: Either pre-processing method may be utilized to derive PAM50 subtypes for future 
studies. The majority of NHS/NHSII tumor and tumor-adjacent tissues were classified as Luminal 
A and Normal-like, respectively.
Impact: Pre-processing methods are important for the accurate assignment of PAM50 subtypes. 
These data provide evidence that either pre-processing method can be used in epidemiological 
studies.
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Introduction
Breast cancer is a heterogeneous disease at both morphological and molecular levels (1,2). 
Given this diversity, many approaches such as MammaPrint (3), Oncotype DX (4) and 
PAM50 (5), have been developed to classify breast tumors to inform prognosis and guide 
treatment. PAM50 is a 50-gene signature that classifies breast cancer into five molecular 
intrinsic subtypes: Luminal A, Luminal B, human epidermal growth factor receptor 2 
(HER2)-enriched, Basal-like and Normal-like (1,5). Each of the five molecular subtypes 
vary by their biological properties and prognoses (6,7). Luminal A generally has the best 
prognosis; HER2-enriched and Basal-like are considered more aggressive diseases. Less 
common subtypes, such as Claudin-low, Interferon-rich and Molecular Apocrine, have also 
been identified using other gene expression profiling assays (8–11).
Molecular subtyping using the PAM50 gene signature can be performed using gene 
expression derived from microarrays, RNASeq or qRT-PCR. Until the recent development of 
Prosigna™, a rapid PAM50-based molecular subtype classifier using the NanoString 
nCounter Dx Analysis System (12), the complexities of using PAM50 and other gene 
signature assays for molecular subtyping have limited their use in clinical practice and led to 
the development of immunohistochemical (IHC) surrogate definitions to classify tumors into 
molecular subtypes (13,14). For example, the immunophenotypic surrogate profile for 
classifying a tumor as Basal-like is one that is estrogen receptor (ER), progesterone receptor 
(PR) and HER2 negative, with positive expression of cytokeratin 5/6 (CK 5/6) and/or 
epidermal growth factor receptor (EGFR) (15). However, studies have reported differences 
in tumor classification when comparing molecular assays and IHC (16,17). There are 
ongoing efforts to refine the IHC definitions to more closely approximate molecular 
subtypes (7,18–21).
In addition to the discrepancies between molecular subtyping using PAM50 and IHC, 
inaccurate pre-processing of gene expression data as well as utilizing non-standard PAM50 
algorithms will result in inconsistent and/or erroneous assignment of molecular subtypes 
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(22–25). In particular, molecular subtype assignment by PAM50 may be affected when the 
clinicopathological distribution (e.g., ER status) of the intended research cohort differs from 
the original cohort used by Parker et al. to derive the PAM50 algorithm. The original cohort 
had an equal distribution of ER+ and ER- tumors (i.e., 50% ER+/50% ER-) (5). To address 
this problem, a modified median gene centering (MMGC) pre-processing method was 
developed (1,2). Later, Zhao et al. proposed a subgroup-specific gene centering (SSGC) pre-
processing method (26).
Although PAM50 subtypes were initially developed to classify breast cancer, molecular 
subtypes can also be reflected in histologically normal tumor-adjacent tissues (henceforth 
referred to as “tumor-adjacent”). Each subtype is associated with a distinct physiological 
response in the tumor-adjacent tissue; and specific gene expression patterns in these tumor-
adjacent regions may be associated with varying risk of recurrence and prognosis (27–30). 
Thus, these prior studies suggest the importance of studying tumor-adjacent tissues in breast 
cancer.
We have previously reported the tumor molecular subtypes using IHC surrogates for 5561 
Nurses’ Health Study (NHS) and NHSII participants diagnosed with breast cancer (31). In 
this study, we describe the tumor and tumor-adjacent PAM50 molecular subtypes in a subset 
of 954 NHS/NHSII participants with gene expression data. Specifically, we:
1. computed and compared breast cancer PAM50 molecular subtypes, proliferation 
scores and risk of relapse with proliferation and tumor size weighted (ROR-PT) 
scores derived from both the MMGC and SSGC pre-processing methods;
2. determined the concordance of tumor molecular subtypes using PAM50 and IHC 
surrogates; and
3. described the tumor PAM50 subtype distribution, proliferation scores and ROR-
PT scores in the NHS/NHSII.
Materials and Methods
Study population
The Human Subjects Committee at Partners Healthcare System and Brigham and Women’s 
Hospital in Boston, MA approved this study. The NHS and NHSII cohorts are ongoing 
prospective studies of US female registered nurses followed biennially by questionnaires to 
query exposures and identify newly diagnosed diseases. NHS was established in 1976 with 
121,700 participants between 30–55 years of age, and NHSII was established in 1989 
(n=116,429, ages 25–42). Written permission was obtained from participants who were 
diagnosed with invasive breast cancer, or their next of kin, to review medical records for 
diagnosis confirmation, retrieval of cancer details, and to collect archival tissue specimens. 
Archival formalin-fixed paraffin embedded (FFPE) breast cancer tissue blocks were 
requested from respective hospitals (32).
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Local and distant recurrences were self-reported by NHS/NHSII participants; no medical 
record review was conducted for recurrences. Recurrence-free survival (RFS) is defined as 
time from diagnosis to reported breast cancer recurrence, diagnosis of cancer in common 
sites of recurrence (i.e., liver, lung, brain or bone) or death from breast cancer without 
reported recurrence. Distant recurrence-free survival (DRFS) is defined as time from initial 
diagnosis to diagnosis of cancer in common sites of recurrence (i.e., liver, lung, brain or 
bone) or death from breast cancer without reported recurrence.
Gene expression data
The protocol to obtain RNA from FFPE tissues was previously published (33). Gene 
expression data were obtained in two batches using microarrays performed in 2012–2014 
using the Glue Grant Human Transcriptome Arrays (HTA) 3.0 pre-release version 
(Affymetrix, Santa Clara, CA) (33) and 2015–2018 (HTA 2.0, Affymetrix) by the Molecular 
Biology Core Facilities, Dana-Farber Cancer Institute, Boston, MA. Gene expression data 
were normalized, summarized into Log2 values using Robust Multi-array Average and 
annotated. All microarrays and sample information are available at the National Center for 
Biotechnology Information Gene Expression Omnibus (accession number: GSE115577).
Molecular subtyping by PAM50, proliferation scores and ROR-PT scores
Molecular subtyping by PAM50 was carried out separately for tumor and tumor-adjacent 
samples. Gene adjustment factors for tumor-adjacent samples were estimated from tumors. 
After adjusting the gene expression dataset using the MMGC or SSGC method, research-
based PAM50 classification was performed. Proliferation scores and ROR-PT scores are 
additional measures that were subsequently developed to further characterize breast tumors 
and are automatically generated by the PAM50 algorithm (34). Thus, proliferation scores 
and ROR-PT scores were only reported for tumor tissues. Proliferation scores were 
computed using three methods: Log2 expression (no centering), MMGC-adjusted 
expression, and SSGC-adjusted expression. The ROR-PT score is calculated using PAM50 
subtype, proliferation score, and pathological tumor size.
Molecular subtyping using IHC surrogates
IHC data were obtained from tissue microarrays (31,32,35). Missing IHCs for ER, PR and 
HER2 (n=144) were replaced with data from medical records. Tumors were classified into 
Luminal A, Luminal B, HER2-enriched and Basal-like as previously defined (14,31,36). For 
tumors missing Ki-67 IHC data (n=545), histologic grade was used as a proxy in 
classification.
Please refer to the Supplementary Methods for gene expression, pre-processing methods and 
IHC surrogate details.
Statistical methods
Confusion matrices were used to determine the concordance of PAM50 subtypes when gene 
expression data were pre-processed using the MMGC or SSGC method, the concordance of 
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molecular subtypes classified using PAM50 and IHC in tumor tissues, and the concordance 
of subtypes in paired tumor and tumor-adjacent tissues (37). The confusion matrix computes 
summaries such as accuracy (the frequency of agreement), and Cohen’s kappa (a measure 
which accounts for the agreement expected to occur by random chance). Spearman’s rho 
was used to determine the correlation between the two methods used to derive proliferation 
scores and ROR-PT scores in tumor tissues.
RFS and DRFS were evaluated at five and ten years because these time points are generally 
utilized in clinical studies. Thus, crude and adjusted Cox proportional hazard models 
evaluated the relationship between PAM50 subtypes or ROR-PT scores/groups with RFS or 
DRFS within five and ten years in the NHS/NHSII. Individuals were censored for RFS or 
DRFS if they were reported to have death from other causes or end of follow-up. Adjusted 
models included age and year of diagnosis, clinical grade, stage, type of surgery 
(lumpectomy, mastectomy, none and unknown) and type of treatment (chemotherapy, 
hormone therapy, radiotherapy, two or more types of therapies, none, and unknown). When 
evaluating tumor PAM50 subtypes in the Cox proportional hazard models, Luminal A was 
set as the reference group. The proportional hazards assumption was tested through 
evaluation of scaled Schoenfeld residuals (38). All tests of statistical significance were two-
sided. Statistical significance was defined as a p-value <0.05. All analyses were conducted 
using R version 3.4.0. Kaplan-Meier curves were plotted using survminer version 0.4.0 
package in R.
Results
This analysis consisted of gene expression data from 954 women who contributed 882 
tumors and 695 histologically normal tumor-adjacent samples. Of these, there were 623 
paired samples. This subset of 954 women with gene expression data was generally 
representative of the NHS/NHSII population diagnosed with breast cancer (Supplementary 
Table S1). The majority of participants in this study had stage I disease, were clinical grade 
2, ER+ and PR+, and HER2-. NHS women had more IHC HER2+ cases compared to NHSII 
(Supplementary Table S2). Amongst the 882 women who contributed tumor samples, RFS 
and DRFS data were unavailable for six women. At 10 years of follow-up, there were 112 
recurrence and 85 distant recurrence events. ROR-PT scores were computed for 863 cases; 
19 cases were not computed due to missing tumor size. Thus, only 857 women were 
included for ROR-PT and RFS/DRFS analyses.
Comparing PAM50 molecular subtypes, proliferation scores and ROR-PT scores derived 
from the two pre-processing methods
PAM50 subtypes derived by both pre-processing methods were highly agreeable. Figure 1 
shows the concordance of PAM50 subtypes in tumor (accuracy = 0.86, kappa = 0.81) and 
tumor-adjacent tissue (accuracy = 0.82, kappa = 0.74). Most tumors were classified as 
Luminal A (46% using MMGC and 40% using SSGC; Figure 1A). Of the 695 tumor-
adjacent tissues, 53% and 39% were classified as Normal-like by MMGC and SSGC, 
respectively (Figure 1B). More tumor samples were assigned as Luminal B or HER2-
enriched using SSGC compared to MMGC, while MMGC assigned more tumor samples as 
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Normal-like. Further investigation into why there was a shift in tumors classified as Luminal 
B to Luminal A (n=44), and more Normal-like calls (n=36) using MMGC revealed that 
proliferation scores computed using SSGC were slightly higher compared to MMGC 
resulting in these cases being classified into more aggressive molecular subtypes when 
SSGC method was used (Supplementary Figures S1A-S1C). In general, proliferation scores 
of tumors were highly correlated between simple Log2 expression (no centering) and each 
pre-processing method (both p<0.01; Supplementary Figure S2). ROR-PT scores for tumors 
were highly correlated between MMGC and SSGC (Spearman’s rho=0.99, p<0.01).
Comparing PAM50 molecular subtypes derived from the two pre-processing methods and 
IHC surrogates
Figures 2A and 2B display the correlation between Luminal A, Luminal B, HER2-enriched 
and Basal-like as classified by PAM50 and IHC surrogates (MMGC: accuracy = 0.54, kappa 
= 0.32; and SSGC: accuracy = 0.53, kappa = 0.32). With kappa at 0.32, there is poor 
agreement between PAM50 and IHC. When the Luminal subtypes were grouped together, 
the correlation between PAM50 and IHC improved to fair agreement (MMGC: accuracy = 
0.81, kappa = 0.53, Figure 2C; SSGC: accuracy = 0.79, kappa = 0.49, Figure 2D). Very 
similar results were obtained when analyses were restricted to women with Ki-67 IHC data 
(n=337; Supplementary Data).
Molecular subtypes in tumor and tumor-adjacent tissues
Amongst 623 paired samples, the most common pairing was Luminal A tumors and Normal-
like tumor-adjacent tissues using both pre-processing methods (Figures 3A and 3B). Women 
with Luminal A or B tumors were more likely to have Normal-like tumor-adjacent subtype 
than women with HER2-enriched or Basal-like tumors. The agreement between paired 
tumor and tumor-adjacent subtypes was 30% using MMGC and 32% using SSGC.
Tumor PAM50 subtypes, ROR-PT scores and prognosis in the NHS/NHSII
Since there was high concordance in PAM50 subtypes between the two pre-processing 
methods, subsequent main tables in the manuscript will display results derived from the 
MMGC method while supplementary tables display results from SSGC. Luminal A and B, 
and HER2-enriched were generally of clinical grade 2 while 38% of grade 3 tumors were of 
the Basal-like subtype (Table 1). Seventy-six percent of IHC ER+ tumors were Luminal A or 
B, while 54% of ER- tumors were Basal-like. Similarly, 77% of IHC PR+ tumors were 
Luminal subtypes and 49% of PR- tumors were Basal-like. In tumors classified as HER2-
enriched, only 42% were IHC HER2+. The association of PAM50 subtypes computed using 
the SSGC method and NHS/NHSII participants are in Supplementary Table S3.
Women with the Basal-like subtype were significantly more likely to have poorer RFS 
outcomes within five years (Table 2A). Although women with HER2-enriched subtypes 
appear to have significantly poorer RFS and DRFS outcomes at both five and ten years 
compared to women with Luminal A subtypes (Tables 2A and 2B), further analyses showed 
that this finding is generally reflective of women diagnosed prior to the introduction of 
targeted therapy for HER2 (i.e., trastuzumab) in 1999 (Supplementary Table S4A). After 
1999, there was no difference in RFS or DRFS rates among women with HER2-enriched 
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subtypes compared to women with Luminal A subtypes (Supplementary Table S4B). The 
relationships between PAM50 subtypes and RFS or DRFS in the NHS/NHSII are illustrated 
in Supplementary Figures S3A-S3D.
ROR-PT categories (low, medium and high) were automatically stratified by the PAM50 
algorithm and confirmed the expected relationships using both pre-processing methods, 
where women predicted as “low” had the best RFS and DRFS outcomes (Figures 4A-4D). 
ROR-PT scores were also analyzed as a continuous variable per 10-unit change in the Cox 
proportional hazard model. In crude models for MMGC, every 10-unit increase in ROR-PT 
scores corresponded to 24% increase in risk of recurrence (95% CI 1.11–1.39) within five 
years and 19% (95% CI 1.09–1.30) within ten years (Table 2A); and 29% increase risk of 
distant recurrence (95% CI 1.14–1.46) within five years and 23% (95% CI 1.11–1.36) within 
ten years (Table 2B). These findings attenuated in the adjusted models, though not all the 
way to the null. Results were very similar when PAM50 and ROR-PT were computed using 
SSGC (Supplementary Tables S5A-S5D).
Discussion
The discovery of molecular subtypes has created a new tool for clinicians and researchers to 
further understand breast cancer biology (39), etiology, risk factors (40), and evaluate 
response to treatment (34,41,42). Thus, the accurate assignment of molecular subtypes is 
important. The distribution of PAM50 subtypes, proliferation scores, and ROR-PT scores 
were highly comparable when computed using either the MMGC or SSGC pre-processing 
method. Furthermore, the agreement between PAM50 classification by gene expression and 
IHC was fair when Luminal A and B were considered as a single group. The majority of the 
NHS/NHSII participants had Luminal A subtype tumors. There was a higher rate of 
recurrence in women with Basal-like subtypes compared to Luminal A subtypes. ROR-PT 
scores were only prognostic in crude analyses.
The application of a pre-processing step to the gene expression data as well as selecting a 
specific preprocessing method (i.e., MMGC or SSGC) prior to subtyping are critical 
components to establish a reproducible informatics workflow for PAM50 classification. 
MMGC and SSGC generally yielded concordant subtypes and highly correlated 
proliferation scores. The associations between the PAM50 subtypes & ROR-PT scores and 
prognosis were similar when subtypes were computed using either method. It remains 
unclear which pre-processing method should be considered superior as there is no gold 
standard measure to compare with. Both pre-processing methods have practical utility and 
either one may be employed to classify breast tumors. We decided to use the MMGC 
method to report our main results as this method is widely utilized by The Cancer Genome 
Atlas breast cancer study team (1,2). SSGC is an elegant alternative to MMGC that is useful 
as an additional check when performing PAM50 subtyping. Future data analyses should take 
note that proliferation estimates are generally higher when computed by the SSGC method 
compared to MMGC – tumors are more likely to be classified into the more aggressive 
molecular subtypes, and tumor-adjacent tissue is less likely to be classified as Normal-like.
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The 2015 St Gallen International Expert Conference Report published recommended IHC 
definitions to more accurately reflect molecular subtypes (7). There are slight differences in 
the IHC definitions for the Luminal subtypes between our study and St Gallen’s 
recommendations. Our PR were manually graded as 0, >1% and >10% while St Gallen’s 
suggests using >20% to classify PR+. We graded Ki-67 as low (<14%) or high (>14%) 
while St Gallen categorizes Ki-67 into low (<14%), intermediate (14–19%) and high 
(≥20%). Ki-67 staining information was unavailable for about 60% of women; tumor grade 
was used as a proxy for these individuals. This may result in the misclassification of IHC 
subtypes for some individuals, and may in part explain the low agreement between 
molecular subtyping by PAM50 and IHC in our study. If IHC surrogate definitions are still 
to be used, further refinement is needed so that breast tumor classification will more closely 
approximate the PAM50 subtypes.
With technological advances in RNA extraction and the availability of the NanoString 
nCounter Dx Analysis System (12), more studies in the future should be able to obtain 
molecular subtypes derived from gene expression instead of relying on IHC surrogates. The 
difference in molecular subtyping by PAM50 and IHC is further demonstrated by this 
current study. The PAM50 distribution of NHS/NHSII participants in this study was 46% 
Luminal A, 18% Luminal B, 14% HER2-enriched, 15% Basal-like and 8% Normal-like 
while our previous study utilized IHC surrogates to classify 5561 tumors reported higher 
percentages of women classified as Luminal A (55%) and B (27%), and lower percentages 
of HER2-enriched (6%) and Basal-like (10%) with 2.9% unclassified tumors (31).
Gene expression data are only available for a subset of the breast cancer cases in NHS/
NHSII, though this subset is generally representative of the overall NHS/NHSII breast 
cancer population. The majority of NHS participants are white postmenopausal women, 
while NHSII participants are mostly white premenopausal women. Our data showed that the 
prevalence of each PAM50 subtype did not differ by participant menopausal status. Given 
that IHC subtype surrogates have been shown to differ by race, future studies should 
investigate potential differences in the distributions of PAM50 subtypes in minority 
populations (43).
As expected, women with tumors of Basal-like subtypes had poorer RFS outcomes 
compared to women with Luminal A subtypes. Women with tumors of HER2-enriched 
subtype only had significantly poorer RFS outcomes at both five and ten years compared to 
women with Luminal A subtypes before 1999. In contrast to other studies, we did not 
observe poorer prognosis for Luminal B tumors at ten years (41,44). This may be attributed 
to the small number of events among women with Luminal B tumors or different pre-
processing method used for PAM50 subtyping.
Molecular subtyping was specifically developed to classify breast cancers. We applied the 
PAM50 algorithm to classify histologically normal tumor-adjacent tissue into molecular 
subtypes. The histologically normal tissue was classified as Normal-like for 40–50% of 
women, depending on the pre-processing method used. This suggests that histologically 
normal tumor-adjacent tissue may not be biologically normal for all women. Expression of 
an estrogen response signature and in vivo triple-negative signature in tumor-adjacent tissue 
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was found to differ across tumor PAM50 subtypes (30). Future work could identify novel 
molecular subtypes unique to tumor-adjacent tissue and determine if these novel subtypes 
within tumor-adjacent tissue may harbor additional insights to therapy response and 
prognosis (28,29).
In summary, we used two pre-processing methods (MMGC and SSGC) to characterize the 
PAM50 breast cancer molecular subtypes of tumor and histologically normal tumor-adjacent 
samples. We have shown that either pre-processing method may be utilized to derive PAM50 
subtypes for future studies. In the NHS/NHSII, the majority of tumor and tumor-adjacent 
tissues were classified as Luminal A and Normal-like, respectively. Women with Luminal A 
or B tumors were more likely to have Normal-like tumor-adjacent tissues than women with 
HER2-enriched or Basal-like tumors. Women with Basal-like subtypes had poorer prognoses 
compared to Luminal A subtypes. The identification of novel tumor-adjacent molecular 
subtypes in the future may provide new insights into breast cancer therapy response and 
prognosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) The correlation of molecular subtypes by PAM50 in tumor (A; accuracy = 0.86, kappa = 
0.81) between modified median or subgroup-specific gene centering pre-processing 
methods. (B) The correlation of molecular subtypes by PAM50 in tumor-adjacent tissue (B; 
accuracy = 0.82, kappa = 0.74) between modified median or subgroup-specific gene 
centering pre-processing methods.
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The correlation between the molecular subtypes (Luminal A, Luminal B, HER2-enriched 
and Basal-like) by PAM50 and immunohistochemistry (IHC) surrogates using modified 
median (A) and subgroup-specific (B) gene centering methods. When the Luminal subtypes 
were grouped together, the correlation between PAM50 and IHC improved to fair agreement 
using modified median (C; accuracy = 0.81, kappa = 0.53) and subgroup-specific (D; 
accuracy = 0.79, kappa = 0.49) gene centering methods. IHC surrogates were defined as: 
Luminal A – ER+ and/or PR+, HER2-, and Ki-67 low (or histologic grade 1 or 2); Luminal 
B – ER+ and/or PR+, and HER2+; or ER+ and/or PR+, HER2-, and Ki-67 high (or 
histologic grade 3); HER2-enriched – ER-, PR- and HER2+; Basal-like – ER-, PR-, HER2-, 
and CK 5/6+ and/or EGFR+.
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(A) PAM50 subtypes of paired samples using modified median gene centering pre-
processing method. (B) PAM50 subtypes of paired samples using subgroup-specific gene 
centering pre-processing method.
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These Kaplan-Meier curves display the relationships between the risk of with proliferation 
and tumor size weighted (ROR-PT) categories (low risk [green lines], medium risk [blue 
lines] and high risk [red lines]) and recurrence-free survival (RFS) or distant recurrence-free 
survival (DRFS) in the Nurses’ Health Studies. ROR-PT was separately computed using the 
modified median (A and B) and subgroup-specific (C and D) gene centering methods. Crude 
hazard ratios are reported in the figures.
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Table 1.
Tumor PAM50 subtypes in the Nurses’ Health Study (NHS)/NHSII cohorts.
Luminal A Luminal B HER2-Enriched Basal-like Normal-like
n 405 157 124 128 68
NHS Cohort, n (%)
 NHS 234 (57.8) 93 (59.2) 81 (65.3) 84 (65.6) 45 (66.2)
 NHSII 171 (42.2) 64 (40.8) 43 (34.7) 44 (34.4) 23 (33.8)
Tumor grade, n (%)
 1: Predominantly well-differentiated 143 (36.4) 21 (13.5) 14 (11.8) 11 (9.4) 22 (36.1)
 2: Moderately differentiated 216 (55.0) 86 (55.1) 72 (60.5) 33 (28.2) 35 (57.4)
 3: Poorly differentiated 34 (8.7) 49 (31.4) 33 (27.7) 73 (62.4) 4 (6.6)
Stage, n (%)
 I 265 (65.6) 89 (56.7) 65 (52.4) 62 (48.8) 47 (69.1)
 II 104 (25.7) 53 (33.8) 40 (32.3) 59 (46.5) 15 (22.1)
 III 32 (7.9) 14 (8.9) 18 (14.5) 6 (4.7) 5 (7.4)
 IV 3 (0.7) 1 (0.6) 1 (0.8) 0 (0.0) 1 (1.5)
Tumor estrogen receptor, n (%)
 Positive 389 (96.5) 150 (96.2) 82 (66.7) 36 (28.3) 52 (76.5)
 Negative 14 (3.5) 6 (3.8) 41 (33.3) 91 (71.7) 16 (23.5)
Tumor progesterone receptor, n (%)
 Positive 382 (95.3) 141 (90.4) 76 (62.3) 33 (26.2) 51 (75.0)
 Negative 19 (4.7) 15 (9.6) 46 (37.7) 93 (73.8) 17 (25.0)
Tumor HER2, n (%)
 Positive 101 (26.5) 40 (27.8) 48 (42.1) 21 (17.8) 14 (23.0)
 Negative 280 (73.5) 104 (72.2) 66 (57.9) 97 (82.2) 47 (77.0)
Tumor Ki-67, n (%)
 High 36 (25.2) 27 (44.3) 19 (38.0) 26 (49.1) 5 (16.7)
 Low 107 (74.8) 34 (55.7) 31 (62.0) 27 (50.9) 25 (83.3)
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